Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 7/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361412 | 0.83 | CXCR2 (0.34) | CXCR2CYP2C9 | |
| SCHEMBL5718374 | 0.78 | CXCR2 (0.34) | CXCR2CYP2C9 | |
| Benzoic Acid SCHEMBL1360672 | 0.77 | MRGPRX4 (0.33) | KDM4C | |
| SCHEMBL1361410 | 0.74 | NSD2 (0.31) | CXCR2CYP2C9 | |
| SCHEMBL1363413 | 0.71 | SLC6A4 (0.36) | CYP2C9 | |
| SCHEMBL1363412 | 0.71 | SLC6A4 (0.36) | CYP2C9 | |
| SCHEMBL1360618 | 0.68 | BCL2 (0.41) | KMT2A | |
| SCHEMBL5430929 | 0.65 | SLC6A4 (0.37) | CYP2C9 | |
| SCHEMBL1561187 | 0.65 | NR3C1 (0.34) | CXCR2CYP2C9 | |
| SCHEMBL5718466 | 0.65 | NR3C1 (0.34) | CXCR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067640-B2 | Method for the separation of intermediates which may be used for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2011-11-29 | — | — | US | disclosed |
| US-20110065937-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065937-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | MAOB, HSD17B14, MAOA | KMT2A 1030/4885MAPT 2356/4885CXCR2 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.